DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,042 filers reported holding DANAHER CORPORATION in Q1 2016. The put-call ratio across all filers is 0.83 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,222,137 | +4.0% | 33,140 | +0.6% | 1.61% | +5.6% |
| Q2 2023 | $7,903,059 | -6.7% | 32,929 | -2.0% | 1.53% | -1.5% |
| Q1 2023 | $8,468,408 | -3.5% | 33,599 | +1.6% | 1.55% | -3.8% |
| Q4 2022 | $8,779,152 | +0.0% | 33,076 | -2.7% | 1.61% | -14.6% |
| Q3 2022 | $8,777,000 | +4.4% | 33,982 | +2.5% | 1.89% | +9.9% |
| Q2 2022 | $8,407,000 | -13.4% | 33,162 | +0.2% | 1.72% | +2.9% |
| Q1 2022 | $9,705,000 | -5.7% | 33,086 | +5.8% | 1.67% | +0.2% |
| Q4 2021 | $10,294,000 | +12.7% | 31,286 | +4.3% | 1.66% | -4.6% |
| Q3 2021 | $9,130,000 | +111.6% | 29,990 | +86.6% | 1.74% | +77.7% |
| Q2 2021 | $4,314,000 | +19.9% | 16,076 | +0.6% | 0.98% | +12.9% |
| Q1 2021 | $3,597,000 | -7.3% | 15,981 | -0.2% | 0.87% | -5.5% |
| Q4 2020 | $3,879,000 | +10.9% | 16,012 | -1.5% | 0.92% | -7.1% |
| Q3 2020 | $3,499,000 | +16.2% | 16,249 | -4.6% | 0.99% | +13.1% |
| Q2 2020 | $3,012,000 | +24.9% | 17,035 | -2.2% | 0.88% | +7.5% |
| Q1 2020 | $2,412,000 | -11.3% | 17,425 | -1.7% | 0.82% | +14.3% |
| Q4 2019 | $2,720,000 | +9.7% | 17,722 | +3.3% | 0.71% | +1.4% |
| Q3 2019 | $2,479,000 | +2.4% | 17,163 | -0.6% | 0.70% | +0.6% |
| Q2 2019 | $2,422,000 | +8.0% | 17,261 | +1.6% | 0.70% | -38.5% |
| Q1 2019 | $2,242,000 | +21.4% | 16,981 | +0.8% | 1.14% | +15.3% |
| Q4 2018 | $1,847,000 | +13.5% | 16,839 | -0.8% | 0.98% | +19.5% |
| Q3 2018 | $1,627,000 | -4.7% | 16,981 | -1.9% | 0.82% | -4.4% |
| Q2 2018 | $1,708,000 | -2.2% | 17,310 | -3.0% | 0.86% | +9.8% |
| Q1 2018 | $1,747,000 | +13.4% | 17,844 | +7.5% | 0.78% | +24.8% |
| Q4 2017 | $1,541,000 | +21.1% | 16,604 | +13.5% | 0.63% | +13.5% |
| Q3 2017 | $1,272,000 | +6.7% | 14,624 | -0.7% | 0.55% | +4.7% |
| Q2 2017 | $1,192,000 | -4.6% | 14,734 | -1.9% | 0.53% | +2.3% |
| Q1 2017 | $1,249,000 | +346.1% | 15,023 | +317.4% | 0.52% | +330.8% |
| Q4 2016 | $280,000 | -36.9% | 3,599 | -36.4% | 0.12% | -38.8% |
| Q3 2016 | $444,000 | -28.4% | 5,663 | -7.7% | 0.20% | -29.5% |
| Q2 2016 | $620,000 | -10.1% | 6,138 | -15.6% | 0.28% | -20.1% |
| Q1 2016 | $690,000 | +1.6% | 7,269 | -0.6% | 0.35% | +2.1% |
| Q4 2015 | $679,000 | +10.8% | 7,315 | +1.0% | 0.34% | +4.9% |
| Q3 2015 | $613,000 | -63.4% | 7,243 | -63.3% | 0.32% | -52.2% |
| Q1 2015 | $1,676,000 | +36.6% | 19,739 | +37.9% | 0.68% | +19.1% |
| Q4 2014 | $1,227,000 | +49.8% | 14,314 | +32.6% | 0.57% | +33.7% |
| Q3 2014 | $819,000 | +54.5% | 10,792 | +61.3% | 0.43% | +58.7% |
| Q2 2014 | $530,000 | +85.3% | 6,692 | +75.3% | 0.27% | +78.1% |
| Q1 2014 | $286,000 | – | 3,817 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |